The glutathione S-transferases (GSTs) are a family of enzymes involved in limiting oxidative damage to tissues. Null alleles for one or more of the GST enzymes, especially GSTM1, reportedly occur more frequently in patients with Sjö gren's syndrome and systemic lupus erythematosus who possess certain autoantibodies. Because systemic sclerosis (SSc) is a disease in which oxidative damage has been hypothesized to contribute both to immune dysfunction and tissue damage, we sought to determine if patients from a multi-ethnic cohort of SSc patients with early disease (р5 years) were more likely than ethnically-matched normal controls to have null alleles for GSTM1 (M1) and/or GSTT1 (T1), and if the null allele status correlated with any major disease features. The data show that while M1 and T1 null genotypes were not significantly increased in SSc compared to ethnically matched controls, their frequencies (especially T1 nulls) were significantly higher among SSc patients with hypertension and pulmonary involvement. This suggests that GST genotype may be a genetic factor that contributes to clinical disease expression in SSc. Genes and Immunity (2001) 2, 236-238.
Oxidative damage may be responsible for both direct tissue injury and the generation of specific autoantigens in scleroderma or systemic sclerosis (SSc) (see Rosen et al 1 for review). It has been hypothesized that ischemiareperfusion injury is responsible for a significant portion of the tissue damage in SSc via the creation of oxidizing intermediate species. Susceptibility to such damage may have several genetic components, including mutations of various isotypes of the enzymes superoxide dismutase, catalase, and the glutathione transferases (GSTs). The final common pathway of many diseases involves cellular disruption mediated by the substrates of these enzymes. M1 and T1 individually detoxify different types of potential carcinogens, and the complete lack of one or a combination of these enzymes has been associated with the development of bladder cancer, skin cancer, leukemia, and other malignancies in populations without autoimmune diseases.
forms, GST-M1 (M1) and GST-T1 (T1), occur frequently in normal populations, though their frequencies vary with ethnicity. Previous studies of normal populations have consistently shown the homozygous null allele frequency for M1 and T1 in Caucasians to be 49-55% and 15-19%, respectively, with approximately 8% of whites being homozygous for both M1 and T1 null alleles. [2] [3] [4] Normal African-American populations have shown homozygous null allele frequencies for M1 and T1 of 27%-35% and 24%, respectively, with 4% being homozygous for both null alleles. [2] [3] [4] Null alleles for GSTs are reportedly more common in Japanese patients with Sjö gren's syndrome (57.5% of patients homozygous null for M1 vs 44.1% of controls, 24.5% of patients vs 15.4% controls null for both M1 and T1 5 ) and in Caucasian patients with systemic lupus erythematosus who possess the anti-Ro positive/anti-La negative autoantibody phenotype. 6 In the latter study, there was no statistically significant difference in the frequency of homozygous null alleles between the control and disease groups, but those patients with the Ro + /Laautoantibody phenotype had a higher frequency of homozygous null alleles for either M1 or T1 as compared with those lupus patients with any other autoantibodies (100% and 41.7% vs 61.1% and 18.9%, respectively).
More recently, null alleles for T1 have been found to correlate with radiographic damage in patients with rheumatoid arthritis when combined with other markers of susceptibility to oxidative damage. 7 T1 is the primary isoform found in circulating red blood cells, 8 making its absence potentially even more important in a disease like systemic sclerosis wherein vascular anomalies (eg, Raynaud's phenomenon, pulmonary hypertension, etc) are prominent clinical features. The absence of normal, circulatory system-based mechanisms to deal with oxidative stress could potentiate organ injury in areas of poor perfusion.
The SSc patients studied here belong to the GENISOS (Genetics versus Environment in Scleroderma Outcome Study) cohort, a prospective outcome study of SSc patients from three distinct ethnic groups. 9 All patients met the proposed American College of Rheumatology (ACR) criteria for SSc 10 and had disease duration of р5 years at study entry. SSc patients and ethnically-matched normal controls were genotyped for M1 and T1 (Table 1) to determine if the frequencies of null alleles for M1 and/or T1 were increased in SSc patients compared to controls. Furthermore, clinical and laboratory data from these patients were analyzed to ascertain if null allele status correlated with major disease features at the time of enrollment into the cohort.
Phenotypic data collected at the time of enrollment included information regarding clinical characteristics and autoantibody status (see below). The extent of skin involvement was assessed by the modified Rodnan skin score 11 and patients were classified as having either limited or diffuse scleroderma according to published criteria. 12 Hypertension was defined as resting blood pressure of Ͼ140/90 mm Hg untreated or a history of treated hypertension whether or not the patient was actually hypertensive at the enrollment visit. Patients were asked about any history of non-dermatological cancer. SSc- For comparisons within each ethnic group P = NS ( 2 ). a Genomic DNA from 152 SSc patients (71 Caucasian, 50 Hispanic, 25 African-American, and six from other ethnic groups) and 219 controls (78 Caucasian, 85 Hispanic, and 56 African-American) was extracted from peripheral blood leukocytes. The presence or absence of GST-M1 and GST-T1 was detected by amplificationresistant polymerase chain reaction (PCR) using published primer sequences and conditions (4 [T1 sense],5). Primers were obtained from IDT Inc, (Coralville, IA, USA) and PCR components from Promega (Madison, WI, USA). Beta globin was amplified as a positive control. 5 The PCR resulted in the production of one to three products per patient corresponding to the 455 bp, 268 bp, and 218 bp segments of GST-T1, beta globin, and GST-M1, respectively, as visualized by 2% agarose gel electrophoresis. Subjects lacking both copies of M1 and/or T1 (and thus missing the expected band) were considered to have homozygous null alleles for one or both genes. Chi-square tests were used to assess for any differences in null allele frequencies between SSc patients and ethnically-matched controls.
Genes and Immunity related organ involvement was documented both by patient historical accounts and by collecting medical records. GI involvement was defined as esophageal dysmotility by barium swallow or manometry; dysphagia; gastroesophageal reflux (GERD); pseudo-obstruction by radiography; and malabsorption syndrome. Cardiac involvement included pericarditis or pericardial effusion by echocardiography, signs of right heart failure, and arrhythmia or left and/or right heart failure (by echocardiography) due to SSc. Pulmonary involvement included documented pulmonary fibrosis and pulmonary hypertension. Musculoskeletal involvement included inflammatory arthritis, objective muscle weakness, myositis, and tendon friction rubs. Renal involvement was defined as serum creatinine у1.5 mg/dL, end stage renal disease, proteinuria Ͼ500 mg per day, or history of scleroderma renal crisis. Anti-topoisomerase, Sm, RNP, Ro, and La antibodies were determined by immunodiffusion (Inova Diagnostics, San Diego, CA, USA), antifibrillarin antibody by immunoprecipitation, 13 and anticentromere pattern by indirect immunofluorescence on HEp-2 cells (Antibodies Inc, Davis, CA, USA).
The data show that the frequencies of null alleles for M1 or T1 either singly or in combination were not significantly different between SSc patients and ethnicallymatched normal controls even when stratified across the three ethnic groups ( Table 1) . The frequencies reported here in the normal controls are similar to those reported earlier. [2] [3] [4] All of the clinical and autoantibody data outlined above were initially evaluated for any correlation with M1 and/or T1 homozygous null allele status using the Chi-square test. Patients with homozygous M1 null alleles were less likely than those with at least one M1 allele to have anti-RNP antibodies (6% (4/65) vs 17% (15/87), P = 0.034 (uncorrected Chi-square)), but the difference was not significant after correction for multiple comparisons. Patients with homozygous null alleles for both M1 and T1 had a trend toward a higher frequency of anticentromere antibodies (36% (5/14) vs 16% (22/138), P = 0.065) and history of non-dermatological malignancy (21% (3/14) vs 7% (9/138), P = 0.066), though the differences were not statistically significant. Despite the trend toward a higher prevalence of anticentromere antibodies in the 'double null' group, a similar trend with respect to limited skin involvement, which correlated with anticentromere antibodies, was not evident.
Those clinical features that were significantly different among those with varying GST genotypes are shown in Table 2 . The initial Chi-square analyses suggested a higher frequency of null allele homozygousity among SSc patients with hypertension and SSc-related pulmonary disease. Mantel-Haenszel Chi-square analyses were utilized to control for the confounding effect of ethnicity on each of these manifestations. The association of homozygous T1 null allele status and hypertension at the time of enrollment appeared to be the strongest. Correction for multiple comparisons weakened the associations shown in Table 2 , though the lower bounds of the odds ratios are Ͼ1 for both hypertension and pulmonary involvement. Those patients homozygous for null alleles for both M1 and T1 simultaneously had similar odds ratios to the T1 null comparison, suggesting that the effect was primarily due to the T1 null genotype alone (data not shown).
The brief disease duration (р5 years) of the GENISOS cohort is one potential limitation of this study since other associations between GST alleles and clinical phenotypes may become apparent as data from long-term follow-up of the cohort is collected. Previous studies of patients without autoimmune diseases have not evaluated the contribution of GST genotype to hypertension. While GST genotype may play some role in predisposing patients with SSc to these manifestations, confounding factors may also be present, not the least of which is the fact that hypertension and renal dysfunction often coexist and contribute to each other.
Evidence implicates oxidation in the onset and course of SSc. 1 This study suggests that an individual's GST genotype may influence the disease manifestations early in the course of disease. These results support the hypothesis that autoimmune diseases are heterogeneous with regard to genetic susceptibility factors and that some genes, though not contributing to one's likelihood of developing a given disorder, may modify their clinical expression.
